BioPharma Resources

Company · JNJ

Johnson & Johnson (Janssen)

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC; Johnson & Johnson Innovative Medicine; Actelion.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

131

60 still marketed

Novel approvals

51

Approvals since 2021

77

Originals and new uses

Phase 3 trials

282

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Rybrevant Faspro new use Priority reviewNov 5, 2026
  • Stelara new use OrphanAug 28, 2026
  • Imaavy new use Priority reviewOrphanAug 24, 2026
  • Tremfya new use May 28, 2026
  • Uptravi new use Priority reviewOrphanMay 23, 2026
  • Stelara new use OrphanApr 15, 2026
  • Icotyde approved NovelPriority reviewMar 17, 2026
  • Tecvayli new use Breakthrough therapyPriority reviewOrphanMar 5, 2026
  • Prezcobix new use Feb 27, 2026
  • Prezcobix approved Feb 27, 2026

Drugs in development (23)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (60)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.